Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOVIGIST: Dovitinib in Refractory/Intolerant GIST
NCT01478373Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Disease Control Rate at 12 weeks. Started Jan 2012; status: completed.
02
Drugs
dovitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT01478373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01478373.